Skip to content

Performance Evaluation of ASSURED Rapid Antigen Based Diagnostic Kit for Detection of Dengue, Chikungunya and Malaria.

A Prospective, Open Label, Multicentric, Performance Evaluation of ASSURED Rapid Antigen Based Diagnostic Kit for Detection of Dengue, Chikungunya and Malaria.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/07/043870
Enrollment
200
Registered
2022-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A920- Chikungunya virus disease Health Condition 2: A90- Dengue fever [classical dengue] Health Condition 3: R508- Other specified fever Health Condition 4: B509- Plasmodium falciparum malaria, unspecified Health Condition 5: B518- Plasmodium vivax malaria with other complications

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Ameliorate Biotech PvtLtd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male or Female, aged 13 years to 80 years (both inclusive). 2.Subjects suffering from fever less than 5 days 3.Subjects with any of the following conditions: a.Subject with or without any medical condition who agrees to participate in this clinical trial and is afebrile. b.Subject with febrile illness or malaria/dengue/chikungunya like illness. c.Pre diagnosed Dengue by any antigen based RDT/ELISA d.Pre diagnosed Malaria by any antigen based RDT/MPS e.Pre diagnosed Chikungunya antigen by ELISA or RT PCR confirmation f.Pre diagnosed coinfection with Dengue, Chikungunya or Malaria in combination with each other.

Exclusion criteria

Exclusion criteria: 1.Uncooperative subjects. 2.Subjects not willing to sign written informed consent. 3.Subjects on ventilator or are terminally ill. 4.Subjects who had undergone recent surgery within past 4 months or are about to have surgery schedule within 10 days.

Design outcomes

Primary

MeasureTime frame
Sensitivity and specificity of the test device will be evaluated against the subsequent equivalent. The results obtained from test and the reference device will be evaluated by the Investigator/Medical microbiologist and will be classified as Negative or Positive.Timepoint: Day 1

Secondary

MeasureTime frame
1.The ease of use of the test device will be accessed through a Usability questionnaire. 2.To determine the complete analysis time of the study sample.Timepoint: Day 1

Countries

India

Contacts

Public ContactMr Hasan Ali Ahmed

Ameliorate Biotech Pvt. Ltd.

rashbehari@amelioratebiotech.com9901551514

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026